arrow
M

Marcus P. Watkins

oncology
H指数:21
被引数:1,889

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma

真实世界证据:帕博利珠单抗、吉西他滨、长春瑞滨和脂质体多柔比星在经典霍奇金淋巴瘤中的应用

2026-03-230
OAAI
Multiomic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance

多组学研究揭示皮肤T细胞淋巴瘤进展和耐药过程中的单细胞克隆进化

Blood
IF23.1
2026-02-110
PRE
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Long-Term Follow-up of Bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC)诱导治疗对先前未治疗的移植符合条件的套细胞淋巴瘤(MCL)患者的长期随访

BLOOD
IF23.1
2024-11-050
PRE
MANTLE CELL, FOLLICULAR, WALDENSTROM'S, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

套细胞、滤泡性、Waldenström's及其他惰性B细胞淋巴瘤:临床与流行病学

BLOOD
IF23.1
2024-11-050
PRE
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
2024-10-181
OAAI
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study
2023-11-152
OAAI
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
2023-09-159
OAAI
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
2023-01-019
OA
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
2022-03-2921
OAAI